GRO Biosciences’ ProGly platform shows promise in MG animal model
A treatment based on GRO Biosciences‘ ProGly program — which uses specially designed proteins to regulate the immune system…
Articles by Marisa Wexler, MS
Japan approves zilucoplan, Rystiggo for adults with hard-to-treat gMG
UCB’s zilucoplan and Rystiggo (rozanolixizumab) both were approved in Japan to treat adults with generalized myasthenia gravis…
Povetacicept shows promise in MG mouse model
Treatment with the experimental therapy povetacicept (ALPN-303) reduced disease activity in a mouse model of myasthenia gravis (MG), according…
Elderly MG patients at high risk of treatment side effects
Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments,…
Soliris now approved for children, adolescents with gMG in Japan
Soliris (eculizumab), already approved in Japan for adults with generalized myasthenia gravis (gMG), has now become the first…
Soliris approved for children, ages 6-17, with generalized MG in EU
The approval of Soliris (eculizumab) in the European Union now extends to children and adolescents, ages 6 to 17,…
CHMP favors Soliris be approved in Europe to treat children with gMG
A branch of the European Medicines Agency (EMA) recommended that the approval of Soliris (eculizumab) be expanded to include…
Increased complement activation linked to antibodies against AChR
People with myasthenia gravis (MG) who are positive for antibodies against the acetylcholine receptor (AChR) — the most common…
Vyvgart for efgartigimod infusion now approved in Israel for gMG
Vyvgart (efgartigimod alfa-fcab) is now approved in Israel for the treatment of generalized myasthenia gravis (gMG), according to…
AAN 2023: Longer-term benefits seen with under-skin efgartigimod
Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of…